-
Cost Utility of Subcutaneous Methotrexate As a Second-Line Treatment for Moderate to Severe Rheumatoid Arthritis in the UK
Sep 9, 2025, 16:22 PM -
Multistakeholder Engagement to Codevelop Specifications for Economic Models: The MASH Case Study
Sep 9, 2025, 16:22 PM -
Improving the Transferability of Global RCT Data to Inform Cost-Effectiveness Models in Japan: A Structured Framework for C2H Submissions
Sep 9, 2025, 16:22 PM -
Assessing the Cost-Effectiveness of Semaglutide 2.4 mg in the Management of People With Obesity and Knee Osteoarthritis in the UK
Sep 9, 2025, 16:22 PM -
LLM Engineering in HEOR: Approaches to Improving Accuracy in Clinical Data Extraction
Sep 9, 2025, 16:22 PM -
The Key Role of Social Participation in Health Technology Assessment: Experiences From South American Countries
Sep 9, 2025, 16:22 PM -
The Changing Prevalence of Multicomorbid Patients in the US
Sep 9, 2025, 16:22 PM -
Economic Evaluations of Individual Service and Training Interventions for Self-Harm and Suicide Prevention: A Systematic Review
Sep 9, 2025, 16:22 PM -
Evaluating GenAI vs. Human Screenshot Review Outputs in eCOA Localization: Does AI Hold the Key to Improved Feedback?
Sep 9, 2025, 16:22 PM -
Reframing Pharmaceutical Pricing: Implications of the 2025 SVR Report for Germany’s Pricing Logic and International Spillovers
Sep 9, 2025, 16:22 PM -
Subsequent Treatments and NICE Appraisals for DLBCL: A Review of Committee Discussions
Sep 9, 2025, 16:22 PM -
A Prevalence-Weighted ICER Approach With Scenario Analyses for HTA Without RCT Evidence
Sep 9, 2025, 16:22 PM -
Artificial Intelligence-Powered Literature Reviews (AILRs): Streamlining Joint Clinical Assessment (JCA) Dossier Preparation for the Next Generation of Pharmaceutical Submissions
Sep 9, 2025, 16:22 PM -
Danicopan in Addition to the Component 5 Inhibitor C5i Ravulizumab for the Treatment of Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Residual Hemolytic Anemia in Greece: A Cost Utility Analysis
Sep 9, 2025, 16:22 PM -
Development of a Content-Valid Patient-Reported Outcome (PRO) Measure for Adults With Glycogen Storage Disease Type 1a (GSD1a): The GSD1a Symptom Diary-Adult Version
Sep 9, 2025, 16:22 PM -
Use of the ESMO-Magnitude of Clinical Benefit Scale to Guide HTA Recommendations on Coverage and Reimbursement for Cancer Medicines in Ireland: A Retrospective Analysis
Sep 9, 2025, 16:22 PM -
Role of PROs in HTA and Reimbursement Decisions Across UK, Germany, France, Italy, and Spain
Sep 9, 2025, 16:22 PM -
Cost-Effectiveness Analysis of Oteseconazole vs. Fluconazole for Patients With Severe Vulvovaginal Candidiasis in China
Sep 9, 2025, 16:22 PM -
Exploratory Assessment of the Societal Impact of Changing Informal Care Hours in the Netherlands
Sep 9, 2025, 16:22 PM -
Years of Life Lost and Productivity TB1 SY2 Costs Due to Premature Cancer-Related Mortality in Morocco
Sep 9, 2025, 16:22 PM
